Cemsidomide Shows Immune Reprogramming

Company C4 Therapeutics Event Type Biomarker Data Disclosure Modality Molecular Glue Degrader Asset Cemsidomide (CFT7455) Target IKZF1 / IKZF3 Disease Area Multiple Myeloma Summary C4 Therapeutics reported biomarker evidence that cemsidomide plus dexamethasone activated CD8 T cells and reprogrammed natural-killer cells across 62 heavily pretreated…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline